If you are responding well glycemically on tirzepatide, the incremental benefit of switching is less clear than for pure weight loss goals
Eric Topol (11:42): Yeah, no, I think this is when we did the research on the committee for the American Association for Advancement of Science (AAAS) award, the Mani L
However, the mortality rates in the DXN and combination treatment (DXN + TIR) groups were 30% and 40%, respectively, on day 12, which was the end of the study (Figure 2)
Peptide tools can exhibit run to run drift when sourcing changes, when batch identity is unclear, or when storage and preparation assumptions vary between operators
In this case, inhibition rather than activation of this protein reduced colonic mucosal immune activation
The STEP 1 trial showed participants lost an average of 14.9% of their body weight over 68 weeks at the 2.4mg dose